AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ankyrin repeat and SAM domain-containing protein 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q68DC2

UPID:

ANKS6_HUMAN

Alternative names:

Ankyrin repeat domain-containing protein 14; SamCystin; Sterile alpha motif domain-containing protein 6

Alternative UPACC:

Q68DC2; A0SE62; Q5VSL0; Q5VSL2; Q5VSL3; Q5VSL4; Q68DB8; Q6P2R2; Q8N9L6; Q96D62

Background:

Ankyrin repeat and SAM domain-containing protein 6, also known as Ankyrin repeat domain-containing protein 14, SamCystin, and Sterile alpha motif domain-containing protein 6, plays a crucial role in renal function. Its unique structure, characterized by ankyrin repeats and a sterile alpha motif (SAM) domain, suggests a significant role in cellular processes.

Therapeutic significance:

Nephronophthisis 16, a chronic tubulo-interstitial nephritis leading to end-stage renal failure, is directly associated with mutations in this protein. Understanding the role of Ankyrin repeat and SAM domain-containing protein 6 could open doors to potential therapeutic strategies for this debilitating disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.